--- a
+++ b/clusters/9knumclustersv2/clust_1041.txt
@@ -0,0 +1,46 @@
+No grade  or higher neuropathy
+Patients with grade  or higher peripheral neuropathy will be excluded in the dose escalation phase of the protocol
+ELIGIBILITY CRITERIA - PHASE I (ARMS A, B, C): Patients must not have grade  or higher peripheral neuropathy
+ELIGIBILITY CRITERIA - PHASE II (ARM D): Patients must not have grade  or higher peripheral neuropathy
+Patients with peripheral neuropathy of grade  or higher
+Grade  or higher peripheral neuropathy at screening
+Uncontrolled Grade  or higher infection
+Active esophagitis grade B or higher
+Patients with grade  or higher neuropathy
+Patients must not have Grade  or higher peripheral neuropathy.
+Grade  or higher pneumonitis
+Grade  or higher peripheral neuropathy
+No symptoms attributable to grade  or higher peripheral neuropathy
+Patients with grade  or higher peripheral neuropathy are excluded
+CTCAE grade  or higher peripheral neuropathy
+Current grade  or higher peripheral neuropathy
+Grade  or higher peripheral neuropathy.
+More than one grade  or higher transaminase elevation
+Patients with grade  or higher peripheral neuropathy
+participants with Grade  or higher residual toxicities from prior therapy (including Grade  or higher peripheral neuropathy or any grade neuropathy with pain; excluding alopecia). This includes recovery from any major surgery. Note: Participants with planned surgical to be conducted under local anesthesia may participate. Kyphoplasty or vertebroplasty are not considered major surgery.
+Grade  or higher persisting prior treatment-related neuropathy
+Grade  or higher peripheral neuropathy
+Paclitaxel arm: grade  or higher neuropathy
+Grade  or higher peripheral neuropathy.
+Grade  or higher peripheral neuropathy
+Patients must not have grade  or higher peripheral neuropathy
+Active Grade  or higher infection.
+Patients who have had grade  or higher peripheral neuropathy within  days prior to registration are not eligible (must have resolved to grade  or lower to register)
+Neuropathy grade  or higher
+Grade  or higher peripheral neuropathy (paclitaxel arm only)
+Grade  or higher neuropathy (CTCAE V.)
+Subjects with T or higher, and N disease
+Current grade II or higher peripheral neuropathy.
+Significant peripheral neuropathy defined as grade  or higher
+Current grade II or higher peripheral neuropathy.
+Peripheral neuropathy that is grade  or higher
+Grade  or higher peripheral neuropathy
+Significant neurotoxicity/neuropathy (Grade  or higher) within  days prior to Day 
+Grade  or higher neuropathy
+Significant neurotoxicity/neuropathy (Grade  or higher) within  days prior to the first dose of study drug
+Current grade  or higher neuropathy
+Grade  or higher peripheral neuropathy
+Grade  or higher peripheral neuropathy at the time of study entry
+Grade  or higher peripheral neuropathy
+Grade II or higher neuropathy
+Significant neurotoxicity/neuropathy (Grade  or higher) within  days of first dose of study drug